horizon pharma plc (HZNP) Key Developments
Horizon Pharma Mulls Acquisition
Mar 13 15
Horizon Pharma plc (NasdaqGS:HZNP) is seeking acquisition. Horizon Pharma plc closed offering of $400 million of 2.50% exchangeable senior notes and expects to use the proceed from the offering for for general corporate purposes and to fund future acquisitions or investments in businesses, products and product candidates, although Horizon has no present commitments or agreements to do so.
Horizon Pharma plc Announces Pre-Clinical Data Show Treatment with Interferon Gamma Improved Signs of Disease Severity of Rare Bone Disease
Mar 7 15
Horizon Pharma plc announced that pre-clinical data from an investigator initiated study demonstrated that treatment with murine interferon gamma, which is an analogue of interferon gamma-1b (ACTIMMUNE), improved the signs of disease severity in a mouse model of Autosomal Dominant Osteopetrosis Type II (ADO2). Osteopetrosis is typically divided into two categories: autosomal recessive osteopetrosis or severe malignant osteopetrosis and autosomal dominant osteopetrosis (further divided into Type I and II (ADO2)). ADO2 is a rare, inherited disease resulting from a gene mutation that, despite an increased bone mass, is characterized by a wide range of symptoms and severity including multiple fractures, impaired vision and osteomyelitis (bone infection). ADO2 is the most common type of Autosomal Dominant Osteopetrosis with an estimated prevalence of up to 5.5 per 100,000. This disease has limited treatment options and as reflected in this study, treatment with calcitriol has not resulted in much clinical improvement. The pre-clinical study evaluated the effect of murine interferon gamma in a knock-in mouse model of the p.G213R mutation in the murine CLCN7 gene that results in severe osteopetrosis and death in homozygous (identical gene pairs) mice and a moderately severe form of osteopetrosis in heterozygous (different gene pairs) mice. Mice (n=10/group) were administered either placebo or varying doses (low, medium, high) of interferon gamma or calcitriol (a form of vitamin D) five times per week for 8 weeks. At the end of the eight-week treatment, X-ray and microcomputed tomography showed that treatment with interferon gamma significantly (p < 0.005) reduced the increase of whole body areal bone mineral density, an important measure of bone strength, across all dosing regimens in both male and female ADO2 mice compared to the vehicle group. Additionally, interferon gamma treatment significantly reduced (p < 0.05) the bone volume over tissue volume gain across all dosing regimens in both male and female ADO2 mice compared to the vehicle group. In contrast, mice treated with low and medium doses of calcitriol showed a trend of higher bone mass including whole body areal bone mineral density and bone volume over tissue volume gain whereas the high dose calcitriol group significantly increased areal bone mineral density and bone volume over tissue volume gain compared to the placebo group. Autosomal Dominant Osteopetrosis Type II is a devastating disease and while these data are early, the findings may be important in exploring future treatment. ACTIMMUNE is approved for severe malignant osteopetrosis, the autosomal recessive form, and often the most severe form of osteopetrosis. Horizon is committed to exploring the full clinical utility of ACTIMMUNE and furthering potential treatment options where unmet needs exist for patients with osteopetrosis.
Horizon Pharma plc Prices Offering of $350 Million of 2.50% Exchangeable Senior Notes
Mar 6 15
Horizon Pharma plc priced its offering of $350 million aggregate principal amount of Exchangeable Senior Notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The size of the offering was increased from the previously announced $300 million aggregate principal amount. The Issuer has also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $50 million aggregate principal amount of the notes. The sale of the notes is expected to close on March 13, 2015, subject to customary closing conditions. The Issuer expects that the net proceeds from this offering will be approximately $338.0 million, after deducting the initial purchasers' discount and estimated offering expenses payable by the Issuer. The notes will be general unsecured senior obligations of the Issuer and accrue interest at an annual rate of 2.50% payable semiannually in arrears on March 15 and September 15 of each year, beginning on September 15, 2015. The notes will mature on March 15, 2022, unless earlier exchanged, repurchased or redeemed.
Horizon Pharma Seeks Acquisitions
Mar 4 15
Horizon Pharma plc (NasdaqGS:HZNP) announced today that Horizon Pharma Investment Ltd intends to offer, subject to market and other considerations, $300 million aggregate principal amount of Exchangeable Senior Notes due 2022 in a private offering to qualified institutional buyers. Horizon currently expects to use the net proceeds from the offering for general corporate purposes and to fund future acquisitions or investments in businesses, products and product candidates, although Horizon has no present commitments or agreements to do so.
Horizon Pharma plc Presents at Mizuho New York Healthcare Conference 2015, Mar-02-2015
Feb 27 15
Horizon Pharma plc Presents at Mizuho New York Healthcare Conference 2015, Mar-02-2015 . Venue: Omni Berkshire Place, 21 East 52nd Street at Madison Ave, New York, NY 10022, United States. Speakers: Robert F. Carey, Chief Business Officer and Executive Vice President.